Selected References:
- Apotex Corporation. Guanfacine extended release. Product label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c492e87-3406-ddb8-aaf2-e609c2ded503. Accessed 15 July 2025.
- Kittel-Schneider S, et al. 2021. Parental ADHD in pregnancy and the postpartum period –A systematic review. Neuroscience and Biobehavioral Rev 124;63-77.
- Lee YR, et al. 2025. Guanfacine Use in the ICU for Management of Sedation Weaning. Clin Drug Investig. 45(4):169-173.
- Ornoy A. 2018. Pharmacological treatment of attention deficit hyperactivity disorder during pregnancy and lactation. Pharm Res 35(3):46.
- Ornoy A, et al. 2021. The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review. Curr Neuropharmacol. 19(11):1794-1804.
- Philipp E. 1980. Guanfacine in the treatment of hypertension due to pre-eclamptic toxaemia in thirty women. Br J clin Pharmac 10: 137S-140S.
- Scoten O, et al. 2024. Attention-deficit/hyperactivity disorder in pregnancy and the postpartum period. Am J Obstet Gynecol. 231(1):19-35.
- Srinivas C, et al. 2025. Attention-Deficit/Hyperactivity Disorder Medication Use in Pregnancy and Risk of Preterm Birth: A Population-Based Cohort Study. Paediatr Perinat Epidemiol. May 14. doi: 10.1111/ppe.70031. Online ahead of print.
